Logo
x

Search

Subscribe Now

Mycovia

Mycovia Reports P-III (ultraVIOLET) Study Results of Vivjoa (oteseconazole) for Recurrent Vulvovaginal Candidiasis

Mycovia Reports P-III (ultraVIOLET) Study Results of Vivjoa (oteseconazole) for Recurrent Vulvovaginal Candidiasis

  • August 26, 2022
Insights+: The US FDA New Drug Approvals in April 2022

Insights+: The US FDA New Drug Approvals in April 2022

  • May 19, 2022
Mycovia’ Vivjoa (oteseconazole) Receives the US FDA’s Approval for the Treatment of Recurrent Vulvovaginal Candidiasis

Mycovia’ Vivjoa (oteseconazole) Receives the US FDA’s Approval for the Treatment of Recurrent Vulvovaginal Candidiasis

  • April 28, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.